| Name | Title | Contact Details |
|---|
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.
3 Prime is a Aston, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation
Q Therapeutics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Greater Washington Maternal-Fetal Medicine and Genetics is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.